Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.

ABSTRACT:

Purpose

The addition of the proteasome inhibitor (PI) bortezomib to standard chemotherapy (ADE: cytarabine [Ara-C], daunorubicin, and etoposide) did not improve overall outcome of pediatric AML patients in the Children's Oncology Group AAML1031 phase 3 randomized clinical trial (AAML1031) . Bortezomib prevents protein degradation, including RelA via the intracellular NF-kB pathway. In this study, we hypothesized that subgroups of pediatric AML patients benefitting from standard therapy plus bortezomib (ADEB) could be identified based on pre-treatment RelA expression and phosphorylation status.

Experimental design

RelA-total and phosphorylation at serine 536 (RelA-pSer⁵³⁶ ) were measured in 483 patient samples using reverse phase protein array technology.

Result

SUBMITTER: van Dijk AD 

PROVIDER: S-EPMC9041833 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature